EscudierB, EisenT, StadlerWM, SzczylikC, OudardS, SiebelsM, NegrierS, ChevreauC, SolskaE, DesaiAA, RollandF, DemkowT, HutsonTE, GoreM, FreemanS, SchwartzB, ShanM, SimantovR, BukowskiRM. TARGET Study Group 2007 Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356:125–134.
2.
LlovetJM, RicciS, MazzaferroV, HilgardP, GaneE, BlancJF, de OliveiraAC, SantoroA, RaoulJL, FornerA, SchwartzM, PortaC, ZeuzemS, BolondiL, GretenTF, GallePR, SeitzJF, BorbathI, HäussingerD, GiannarisT, ShanM, MoscoviciM, VoliotisD, BruixJ. SHARP Investigators Study Group 2008 Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359:378–390.
3.
TamaskarI, BukowskiR, ElsonP, IoachimescuAG, WoodL, DreicerR, MekhailT, GarciaJ, RiniBI. 2008. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol, 19:265–268.
4.
ChengAL, KangYK, ChenZ, TsaoCJ, QinS, KimJS, LuoR, FengJ, YeS, YangTS, XuJ, SunY, LiangH, LiuJ, WangJ, TakWY, PanH, BurockK, ZouJ, VoliotisD, GuanZ. 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10:25–34.
